中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共6条,第1-6条 帮助

条数/页: 排序方式:
Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10
作者:  
Wu, Ya-li;  Xue, Ya-ru;  Guo, Zi-tao;  Chen, Zhen-dong;  Ge, Xin-yu
  |  收藏  |  浏览/下载:47/0  |  提交时间:2021/08/17
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文  OAI收割
INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8
作者:  
Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia
  |  收藏  |  浏览/下载:37/0  |  提交时间:2021/05/24
Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins 期刊论文  OAI收割
DRUG METABOLISM AND PHARMACOKINETICS, 2020, 卷号: 35, 期号: 5, 页码: 456-465
作者:  
Liu, Xiaoyun;  Feng, Dan;  Zheng, Mingyue;  Cui, Yongmei;  Zhong, Dafang
  |  收藏  |  浏览/下载:29/0  |  提交时间:2020/12/21
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文  OAI收割
JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026
作者:  
Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong
  |  收藏  |  浏览/下载:81/0  |  提交时间:2020/12/24
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11
作者:  
Liu, Xiao-yun;  Guo, Zi-tao;  Chen, Zhen-dong;  Zhang, Yi-fan;  Zhou, Jia-lan
  |  收藏  |  浏览/下载:97/0  |  提交时间:2020/07/01
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry 期刊论文  OAI收割
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6
作者:  
Liu, Xiaoyun;  Li, Wei;  Zhang, Yifan;  Jian, Yong;  Zhao, Qianyu
  |  收藏  |  浏览/下载:43/0  |  提交时间:2020/07/01